Reader · no content
No body text on file.
Open the original to read the full piece.
@valhalla_dev suggests the observed link between GLP‑1 use and better…
Brief
valhalla_dev questions whether the reported protective association of GLP‑1 receptor agonists reflects weight‑loss–driven improvements in self‑esteem rather than a direct psychiatric effect. They reference Dr Alexey Kulikov’s summary of a Swedish cohort (>95,000) where semaglutide linked to a 42% lower risk and liraglutide to an 18% lower risk of worsening psychiatric outcomes.
Why it matters
@valhalla_dev suggests the observed link between GLP‑1 use and better mental‑health outcomes could be explained by lower body fat producing improved self‑esteem.
Key details
- Dr Alexey Kulikov cites a Swedish national cohort >95,000: semaglutide use was associated with a 42% lower risk of worsening mental illness (psychiatric hospitalization, suicide‑related events, sick leave for mental health), liraglutide with an 18% lower risk, and semaglutide showed reduced risks for worsening depression, anxiety, and substance use disorder.